

Date: 02/04/2019

FREEDOM OF INFORMATION REQUEST FOI/014724 - Vyxeos to treat patients

Please find below a request for information regarding the use of Vyxeos to treat patients with Acute Myeloid Leukemia (AML) at your Trust. Four Communications is carrying out this request on behalf of Jazz Pharmaceuticals.

1. Is Vyxeos an approved therapy on the trust formulary for patients with Acute Myeloid Leukemia (AML)?
 - As Vyxeos is nationally approved via CDF, it is automatically offered as a treatment within the Trust

2. What e-prescribing system does the Trust use? - Chemocare

3. Is Vyxeos now available to be prescribed through the Trust's e-prescribing system? - Vyxeos is not currently available to be prescribed through the system as we are yet to use it within the Trust. The Trust is in the process of setting this up